Grant of options
Oxford, UK - 05 November 2024: Oxford Biomedica plc ("OXB" or the "Company"; LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces that on 03 October 2024 nil-cost share options over ordinary shares of 50 pence each in the Company were granted under the OXB 2024 Long Term Incentive Plan ("LTIP").
2024 RSU Awards
|
Type of RSU |
Name of individual |
Title |
Number of shares subject to the DBP/LTIP/RSU award prior to 2024 award |
Number of shares subject to the 2024 LTIP award |
Total shares over which options now held |
Percentage of current issued share capital under option |
|
US RSU |
Mark Caswell |
Site Head of UK Operations |
74,172* |
23,352 |
97,524 |
0.09% |
|
US RSU |
John Maravich |
Site Head of US Operations |
15,020 |
14,862 |
29,882 |
0.03% |
|
UK RSU |
Sabine Sydow |
Chief of Staff |
12,516 |
7,599 |
20,115 |
0.02% |
*74,172 granted to Mark Caswell prior to 2024 Award comprise LTIP award with performance conditions attached.
The UK RSU Awards will "vest" on 3 October 2027 and are not subject to performance conditions. The US RSU Awards are divided into four tranches, not subject to performance conditions and each tranche will "vest" on the anniversary of the award on 03/10/2025, 03/10/2026, 03/10/2027 and 03/10/2028 respectively
The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
Notification of Dealing Form
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Mark Caswell |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Site Head of UK Operations |
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. |
||||
|
c) |
Price(s) and volumes(s) |
2024 LTIP US RSU Award
|
||||
|
d) |
Aggregated information - Aggregate volume
- Price
|
Awards granted over 23,352 shares in total
N/A
|
||||
|
e) |
Date of the transaction |
2024-10-03 |
||||
|
f) |
Place of the transaction |
Outside of trading venue |
||||
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
John Maravich |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Site Head of US Operations |
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. |
||||
|
c) |
Price(s) and volumes(s) |
2024 LTIP US RSU Award
|
||||
|
d) |
Aggregated information - Aggregate volume
- Price
|
Awards granted over 14,862 shares in total
N/A
|
||||
|
e) |
Date of the transaction |
2024-10-03 |
||||
|
f) |
Place of the transaction |
Outside of trading venue |
||||
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Sabine Sydow |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief of Staff |
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards. |
||||
|
c) |
Price(s) and volumes(s) |
2024 LTIP UK RSU Award
|
||||
|
d) |
Aggregated information - Aggregate volume
- Price
|
Awards granted over 7,599 shares in total
N/A
|
||||
|
e) |
Date of the transaction |
2024-10-03 |
||||
|
f) |
Place of the transaction |
Outside of trading venue |
||||
-Ends-
Enquiries:
|
Oxford Biomedica plc: Natalie Walter, Company Secretary |
Tel: +44 (0)1865 783 000 |
About OXB
OXB (LSE: OXB) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, OXB has more than 25 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities span from early stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetravecta™ system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.
OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
